Discrimination between patients with activeLN and active non-LNMonitoring disease activity and response totherapyAccurately stratifying patients with regardsto extent and nature of renal injury without in vivo interventionInforming long-term prognosis
[Detail]
Specific antibody to detect Cep164 by antibody-antigen complex formation.
[Detail]
Revealing molecular-level signature of tumorLow cost, disposable, ease of mass productionMultifunctional diagnostic platform for different blood related diseases
[Detail]
Researchers from the Monash Institute of Pharmaceutical Sciences and collaborators, have identified novel peptides that are highly potent and selective inhibitors of the Kv1.3 potassium channel.
[Detail]
 |
| |< <- | [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] | -> >| |
